3,451 results on '"Terbuch, A."'
Search Results
252. Serum Biomarkers in a Radiological Pattern of Non-Fibrotic Hypersensitivity Pneumonitis: Implications for Mechanistic Difference and Differential Diagnosis.
- Author
-
Takimoto, Takayuki and Nakamura, Yukihiro
- Subjects
HYPERSENSITIVITY pneumonitis ,DIFFERENTIAL diagnosis ,LUNG diseases ,LUNGS ,BIOMARKERS ,INTRAVENOUS therapy - Abstract
Hypersensitivity pneumonitis (HP) is a consequence of immune-mediated reactions caused by recurrent exposure to environmental agents. Recently, clinical practice guidelines for the diagnosis of HP were published and increased interest in HP. On the other hand, novel therapies have recently emerged for various diseases, and the management of drug-related pneumonitis (DRP) has become increasingly important. Among DRP, the HP pattern (DRP-HP) shows small, poorly defined centrilobular nodules with or without widespread areas of ground-glass opacity or lobular areas of decreased attenuation and vascularity. A similar radiological pattern of non-fibrotic HP can be induced, irrespective of inhalation (non-fibrotic HP) or intravenous administration (DRP-HP). However, their difference has not been well described, although the distribution of lesions in the lungs was slightly different between these two conditions. In this review, we focus on serum biomarkers of lung epithelial cells in order to investigate the difference between DRP-HP and non-fibrotic HP (common-HP). Serum levels of Krebs von den Lungen 6 (KL-6) might be relatively lower (occasionally normal) in DRP-HP than in common-HP, implying a mechanistic difference. KL-6 could be useful in discriminating between DRP and non-fibrotic HP (common type). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
253. Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis—Results from the Adjuvant SUCCESS A Trial.
- Author
-
Trapp, Elisabeth K., Fasching, Peter A., Fehm, Tanja, Schneeweiss, Andreas, Mueller, Volkmar, Harbeck, Nadia, Lorenz, Ralf, Schumacher, Claudia, Heinrich, Georg, Schochter, Fabienne, de Gregorio, Amelie, Tzschaschel, Marie, Rack, Brigitte, Janni, Wolfgang, and Friedl, Thomas W. P.
- Subjects
BREAST cancer prognosis ,METASTASIS ,CANCER relapse ,CANCER patients ,CELL lines ,TUMOR markers ,BODY fluid examination - Abstract
Simple Summary: Due to recent advances in breast cancer detection and treatment strategies, the number of breast cancer survivors has increased over the past decades. However, breast cancer follow-up guidelines have not changed for years. The presence of CTCs detected during follow-up has been shown to indicate poor prognosis in high-risk breast cancer patients. Here, we evaluated if the presence of CTCs also indicates the site of metastatic disease by analyzing CTC status and metastatic location in 206 patients with distant recurrence from the large adjuvant breast cancer trial SUCCESS A. Patients who were CTC-positive both before and after chemotherapy were more likely to show bone-only first distant disease (37.5% vs. 21.0%) and first distant disease at multiple sites (31.3% vs. 12.6%) than patients without CTCs. These data indicate that CTCs might serve as a liquid biopsy surveillance-marker enabling risk-stratification for deciding on further adjuvant add-on-treatment. The prognostic relevance of circulating tumor cells (CTCs) in breast cancer is well established. However, little is known about the association of CTCs and site of first metastasis. In the SUCCESS A trial, 373 out of 3754 randomized high-risk breast cancer patients developed metastatic disease. CTC status was assessed by the FDA-approved CellSearch
® -System (Menarini Silicon Biosystems, Bologna, Italy) in 206 of these patients before chemotherapy and additionally in 159 patients after chemotherapy. CTCs were detected in 70 (34.0%) of 206 patients before (median 2 CTCs, 1–827) and in 44 (27.7%) of 159 patients after chemotherapy (median 1 CTC, 1–124); 16 (10.1%) of 159 patients were CTC-positive at both timepoints. The site of first distant disease was bone-only, visceral-only, and other-site-only in 44 (21.4%), 60 (29.1%), and 74 (35.9%) patients, respectively, while 28 (13.6%) patients had multiple sites of first metastatic disease. Patients with CTCs at both timepoints more often showed bone-only first distant disease (37.5% vs. 21.0%) and first distant disease at multiple sites (31.3% vs. 12.6%) than patients without CTCs before and/or after chemotherapy (p = 0.027). In conclusion, the presence of CTCs before and after chemotherapy is associated with multiple-site or bone-only first-distant disease and may trigger intensified follow-up and perhaps further treatment. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
254. The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response.
- Author
-
Bradbury, Alice, Zenke, Frank T., Curtin, Nicola J., and Drew, Yvette
- Subjects
OVARIAN cancer ,BIOMARKERS ,ATAXIA telangiectasia ,DNA replication ,DNA repair ,CANCER cells - Abstract
Ataxia telangiectasia and Rad-3 related kinase (ATR) signals DNA lesions and replication stress (RS) to the S and G2/M checkpoints and DNA repair pathways making it a promising target to exploit the dysregulated DNA damage response in cancer. ATR inhibitors (ATRi) are under clinical investigation as monotherapy and in combination with other anticancer agents. Molecular determinants of sensitivity to ATRi are common in ovarian cancer, suggesting the therapeutic potential of ATRi. We investigated the cytotoxicity of the ATRi, VE-821, in a panel of human ovarian cancer cell lines. High grade serous (HGS) cell lines were significantly more sensitive to VE-821 than non-HGS (p ≤ 0.0001) but previously identified determinants of sensitivity (TP53, ATM and BRCA1) were not predictive. Only low RAD51 (p = 0.041), TopBP1 (p = 0.026) and APOBEC3B (p = 0.015) protein expression were associated with increased VE-821 sensitivity. HGS cells had increased levels of RS (pRPA
Ser4/8 and γH2AX nuclear immunofluorescence), and elevated RS predicted sensitivity to VE-821 independently of the cell line subtype. These data suggest that functional assessment of RS biomarkers may be a better predictive biomarker of ATRi response than any single aberrant gene in ovarian cancer and potentially other cancers. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
255. Targeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and Radiotherapy.
- Author
-
Nickoloff, Jac A.
- Subjects
DNA replication ,CHECKPOINT kinase 1 ,HEAT shock proteins ,DNA repair ,SMALL molecules ,DNA damage ,REACTIVE oxygen species ,CANCER cells - Abstract
Proliferating cells regularly experience replication stress caused by spontaneous DNA damage that results from endogenous reactive oxygen species (ROS), DNA sequences that can assume secondary and tertiary structures, and collisions between opposing transcription and replication machineries. Cancer cells face additional replication stress, including oncogenic stress that results from the dysregulation of fork progression and origin firing, and from DNA damage induced by radiotherapy and most cancer chemotherapeutic agents. Cells respond to such stress by activating a complex network of sensor, signaling and effector pathways that protect genome integrity. These responses include slowing or stopping active replication forks, protecting stalled replication forks from collapse, preventing late origin replication firing, stimulating DNA repair pathways that promote the repair and restart of stalled or collapsed replication forks, and activating dormant origins to rescue adjacent stressed forks. Currently, most cancer patients are treated with genotoxic chemotherapeutics and/or ionizing radiation, and cancer cells can gain resistance to the resulting replication stress by activating pro-survival replication stress pathways. Thus, there has been substantial effort to develop small molecule inhibitors of key replication stress proteins to enhance tumor cell killing by these agents. Replication stress targets include ATR, the master kinase that regulates both normal replication and replication stress responses; the downstream signaling kinase Chk1; nucleases that process stressed replication forks (MUS81, EEPD1, Metnase); the homologous recombination catalyst RAD51; and other factors including ATM, DNA-PKcs, and PARP1. This review provides an overview of replication stress response pathways and discusses recent pre-clinical studies and clinical trials aimed at improving cancer therapy by targeting replication stress response factors. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
256. Genomic Assessment of Cancer Susceptibility in the Threatened Catalina Island Fox (Urocyon littoralis catalinae).
- Author
-
Hendricks, Sarah A., King, Julie L., Duncan, Calvin L., Vickers, Winston, Hohenlohe, Paul A., and Davis, Brian W.
- Subjects
CANCER susceptibility ,BIOLOGICAL extinction ,WHOLE genome sequencing ,GENETIC variation ,DISEASE risk factors ,HOMOZYGOSITY - Abstract
Small effective population sizes raise the probability of extinction by increasing the frequency of potentially deleterious alleles and reducing fitness. However, the extent to which cancers play a role in the fitness reduction of genetically depauperate wildlife populations is unknown. Santa Catalina island foxes (Urocyon littoralis catalinae) sampled in 2007–2008 have a high prevalence of ceruminous gland tumors, which was not detected in the population prior to a recent bottleneck caused by a canine distemper epidemic. The disease appears to be associated with inflammation from chronic ear mite (Otodectes) infections and secondary elevated levels of Staphyloccus pseudointermedius bacterial infections. However, no other environmental factors to date have been found to be associated with elevated cancer risk in this population. Here, we used whole genome sequencing of the case and control individuals from two islands to identify candidate loci associated with cancer based on genetic divergence, nucleotide diversity, allele frequency spectrum, and runs of homozygosity. We identified several candidate loci based on genomic signatures and putative gene functions, suggesting that cancer susceptibility in this population may be polygenic. Due to the efforts of a recovery program and weak fitness effects of late-onset disease, the population size has increased, which may allow selection to be more effective in removing these presumably slightly deleterious alleles. Long-term monitoring of the disease alleles, as well as overall genetic diversity, will provide crucial information for the long-term persistence of this threatened population. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
257. Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer.
- Author
-
Zografos, Eleni, Andrikopoulou, Angeliki, Papatheodoridi, Alkistis Maria, Kaparelou, Maria, Bletsa, Garyfalia, Liontos, Michalis, Dimopoulos, Meletios-Athanasios, and Zagouri, Flora
- Subjects
SOMATIC mutation ,NUCLEOTIDE sequencing ,BREAST cancer ,GENETIC testing ,CANCER genes ,TUMOR suppressor genes ,BREAST - Abstract
Breast cancer has distinct etiology, prognoses, and clinical outcomes at premenopausal ages. Determination of the frequency of germline and somatic mutations will refine our understanding of the genetic contribution to premenopausal breast cancer susceptibility. We applied a comprehensive next generation sequencing-based approach to analyze blood and/or tissue samples of 54 premenopausal breast cancer patients treated in our clinic. Genetic testing results were descriptively analyzed in correlation with clinicopathological data. In the present study, 42.5% of premenopausal breast cancer patients tested carried pathogenic mutations in cancer predisposition genes (CHEK2, BRCA1, TP53, and MUTYH). Germline variants of unknown/uncertain significance (VUSs) in eight different cancer susceptibility genes, namely BRCA1, BRCA2, CHEK2, RAD51C, RAD51D, ATM, BRIP1, and PMS2, were also identified in 14 premenopausal patients (35%). Of the breast tumors tested, 61.8% harbored pathogenic somatic variants in tumor suppressor genes (TP53, NF1, RB), genes involved in DNA repair (BRCA1, BRCA2, ATM, RAD50), cell proliferation (PTEN, PIK3C FGFR3, AKT1, ROS1, ERBB2, NOTCH1), and cell adhesion (CTNNB1). This descriptive study employs the powerful NGS technology to highlight the high frequency of premenopausal cases attributable to genetic predisposition. Mutation identification in a larger cohort may further ensure that these patients receive tailored treatment according to their menopausal status. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
258. The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
- Author
-
Sartori G, Tarantelli C, Spriano F, Gaudio E, Cascione L, Mascia M, Barreca M, Arribas AJ, Licenziato L, Golino G, Ferragamo A, Pileri S, Damia G, Zucca E, Stathis A, Politz O, Wengner AM, and Bertoni F
- Subjects
- Humans, Phosphatidylinositol 3-Kinases genetics, Ataxia Telangiectasia Mutated Proteins genetics, Protein Kinase Inhibitors therapeutic use, DNA Damage, Neoplasms drug therapy, Lymphoma drug therapy
- Abstract
The DNA damage response (DDR) is the cellular process of preserving an intact genome and is often deregulated in lymphoma cells. The ataxia telangiectasia and Rad3-related (ATR) kinase is a crucial factor of DDR in the response to DNA single-strand breaks. ATR inhibitors are agents that have shown considerable clinical potential in this context. We characterized the activity of the ATR inhibitor elimusertib (BAY 1895344) in a large panel of lymphoma cell lines. Furthermore, we evaluated its activity combined with the clinically approved PI3K inhibitor copanlisib in vitro and in vivo. Elimusertib exhibits potent anti-tumour activity across various lymphoma subtypes, which is associated with the expression of genes related to replication stress, cell cycle regulation and, as also sustained by CRISPR Cas9 experiments, CDKN2A loss. In several tumour models, elimusertib demonstrated widespread anti-tumour activity stronger than ceralasertib, another ATR inhibitor. This activity is present in both DDR-proficient and DDR-deficient lymphoma models. Furthermore, a combination of ATR and PI3K inhibition by treatment with elimusertib and copanlisib has in vitro and in vivo anti-tumour activity, providing a potential new treatment option for lymphoma patients., (© 2023 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
259. The Therapeutic Effects of Withaferin A against Cancer: Overview and Updates.
- Author
-
Abeesh P and Guruvayoorappan C
- Subjects
- Humans, Animals, Apoptosis drug effects, Signal Transduction drug effects, Antineoplastic Agents therapeutic use, Antineoplastic Agents pharmacology, Neovascularization, Pathologic drug therapy, Withanolides therapeutic use, Withanolides pharmacology, Neoplasms drug therapy
- Abstract
Cancer is a rapidly rising health problem among the global population, and this burden causes a significant challenge for public health. Current chemotherapeutic agents have different limitations, including drug resistance and severe side effects, and it demands a robust approach to accessing promising anti-cancer therapeutics. The natural compounds have been extensively studied to identify improved therapeutic agents for cancer therapy. Withaferin A (WA) is a steroidal lactone found in Withania somnifera and possesses anti-inflammatory, antioxidant, anti-angiogenesis, and anticancer properties. Multiple studies have shown that WA treatment attenuated various cancer hallmarks by inducing apoptosis and reducing angiogenesis and metastasis with reduced side effects. WA is a promising agent for the treatment of various cancer, and it targets various signaling pathways. With recent updates, the current review highlights the therapeutic implications of WA and its molecular targets in different cancer., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2024
- Full Text
- View/download PDF
260. Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors.
- Author
-
Yihui Gu, Chengjiang Wei, Manhon Chung, Haibo Li, Zizhen Guo, Manmei Long, Yuehua Li, Wei Wang, Aimaier, Rehanguli, Qingfeng Li, and Zhichao Wang
- Subjects
PERIPHERAL nerve tumors ,SCHWANNOMAS ,GTPASE-activating protein ,RAS proteins ,NEUROFIBROMATOSIS 1 ,FOCAL adhesion kinase - Abstract
Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft-tissue sarcomas which lack effective drugs. Loss of the RAS GTPase-activating protein NF1 and subsequent overactivation of mitogen-activated protein kinase kinase (MAPK) signaling exist nearly uniformly in MPNST, making MAPK inhibition a promising therapeutic intervention. However, the efficacy of MEK inhibitor (MEKi) monotherapy was limited in MPNST and the relative mechanisms remained largely unexplored. In this study, we generated three MEKi-resistant cell models and investigated the mechanisms of MEKi resistance using high-throughput transcriptomic sequencing. We discovered that cell apoptosis and cell cycle arrest induced by MEKi were rescued in MEKi-resistant cells and the upregulation of LAMA4/ITGB1/FAK/SRC signaling conferred resistance to MEKi. In addition, concurrent inhibition of MAPK signaling and FAK/SRC cascade could sensitize MPNST cells to MEKi. Our findings provide potential solutions to overcome MEKi resistance and effective combination therapeutic strategies for treating MPNSTs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
261. Differentielle Objektmarkierung im Spanischunterricht.
- Author
-
Reina, Javier Caro
- Subjects
SPANISH language ,TERMS & phrases ,ANIMACY (Grammar) ,FOREIGN language education ,GRAMMATICALIZATION ,GERMAN language - Abstract
The article focuses on the differentials in object marking in the Spanish language, where definite nominal phrases are differentially marked when they refer to human referents. Topics include Different grammatical elements play a role in phenomenon, including animacy, specificity, afficiency, agentivity, telicity, and topicality; and differential object marking (DOM) is a challenging aspect for German learners of Spanish and often leads to ungrammatical uses of DOM, such as hypercorrection.
- Published
- 2022
262. Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial.
- Author
-
Capelletto, Enrica, Bironzo, Paolo, Denis, Louis, Koustenis, Andrew, Bungaro, Maristella, and Novello, Silvia
- Abstract
KRAS mutations occur in approximately 30% of lung adenocarcinomas, mainly in codon 12 (83% of cases), p.G12C being the prevalent one (40%), followed by p.G12V and p.G12D (22 and 16%, respectively). Treatment options for advanced KRAS mutant non-small-cell lung cancer (KRAS-MT NSCLC) are limited to chemotherapy and immune checkpoint inhibitors (CPIs). However, clinical trials exploring specific targeted agents are expected to change the treatment landscape of this disease. Here, we describe the design and scientific rationale of the randomized, phase II, open label, RAMP-202 study, which will evaluate the efficacy and safety of VS-6766 versus VS-6766 in combination with defactinib in advanced KRAS-MT NSCLC patients after failure of prior platinum-based chemotherapy and CPI. The alteration of KRAS gene occurs in approximately 30% of lung cancers. According to international guidelines, treatment options for patients with advanced KRAS mutant lung cancer are now limited to chemotherapy and immunotherapy. However, clinical trials are exploring how specific targeted agents are expected to change the treatment landscape of this disease. Here, we describe the design and scientific rationale of the RAMP-202 study, which will evaluate the efficacy and safety of two new biological agents for patients with KRAS mutant lung cancer. The enrolled patients were those who had failure of prior platinum-based chemotherapy and immunotherapy. Clinical Trial Registration: NCT04620330 (ClinicalTrials.gov). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
263. DigiMir Test: Establishing a Novel Pipeline for MiR-371a Quantification Using Droplet Digital PCR in Liquid Biopsies From Testicular Germ Cell Tumor Patients.
- Author
-
Sequeira, José Pedro, Lobo, João, Constâncio, Vera, Brito-Rocha, Tiago, Carvalho-Maia, Carina, Braga, Isaac, Maurício, Joaquina, Henrique, Rui, and Jerónimo, Carmen
- Subjects
TUMOR markers ,BIOMARKERS ,GERM cell tumors ,LIQUIDS ,BIOPSY ,PATIENT monitoring - Abstract
Testicular germ cell tumors (TGCTs) are the most common cancers in young-adult male patients aged between 15 and 39 years. Hsa-miR-371a-3p is currently the most reliable biomarker for diagnosis and monitoring of these patients non-invasively in liquid biopsies, and it is destined to be introduced in the clinic due to improved performance compared to the classical serum tumor markers available. Current studies have focused on real-time quantitative PCR (RT-qPCR) protocols for its determination; still, some challenges remain, since these protocols often require preamplification steps (costly and time-consuming), and report relative levels normalized to a housekeeping microRNA, not always performed the same way. Droplet digital PCR (ddPCR) shows the promise to overcome these challenges, skipping normalization and preamplifications, but has hardly been explored in the field of TGCTs. In this work, we provide a report of a ddPCR-based pipeline for the quantification of hsa-miR-371a-3p (the DigiMir pipeline) and compare it with two RT-qPCR protocols. A total of 107 plasma samples were investigated in the validation setting. The DigiMir pipeline detected TGCTs in a manner representative of tumor burden, with a sensitivity and specificity of 94% and 100%, respectively, outperforming the combined sensitivity of all three classical serum tumor markers (61.5%). Therefore, in this proof-of-concept investigation, we have shown that the DigiMir pipeline constitutes a new promising methodology to accurately report hsa-miR-371a-3p in the clinical setting. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
264. A preclinical model of peripheral T‐cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.
- Author
-
Kuczynski, Elizabeth A, Morlino, Giulia, Peter, Alison, Coenen‐Stass, Anna M L, Moss, Jennifer I, Wali, Neha, Delpuech, Oona, Reddy, Avinash, Solanki, Anisha, Sinclair, Charles, Calado, Dinis P, and Carnevalli, Larissa S
- Abstract
Peripheral T‐cell lymphoma (PTCL) represents a rare group of heterogeneous diseases in urgent need of effective treatments. A scarcity of disease‐relevant preclinical models hinders research advances. Here, we isolated a novel mouse (m)PTCL by serially transplanting a lymphoma from a germinal center B‐cell hyperplasia model (Cγ1‐Cre Blimp1fl/fl) through immune‐competent mice. Lymphoma cells were identified as clonal TCRβ+ T‐helper cells expressing T‐follicular helper markers. We also observed coincident B‐cell activation and development of a de novo B‐cell lymphoma in the model, reminiscent of B‐cell activation/lymphomagenesis found in human PTCL. Molecular profiling linked the mPTCL to the high‐risk "GATA3" subtype of PTCL, showing GATA3 and Th2 gene expression, PI3K/mTOR pathway enrichment, hyperactivated MYC, and genome instability. Exome sequencing identified a human‐relevant oncogenic β‐catenin mutation possibly involved in T‐cell lymphomagenesis. Prolonged treatment responses were achieved in vivo by targeting ATR in the DNA damage response (DDR), a result corroborated in PTCL cell lines. This work provides mechanistic insight into the molecular and immunological drivers of T‐cell lymphomagenesis and proposes DDR inhibition as an effective and readily translatable therapy in PTCL. SYNOPSIS: A murine peripheral T‐cell lymphoma (mPTCL) arose coincident to B‐cell hyperplasia and was developed into a transplantable preclinical model. mPTCL and human PTCL lines responded to ATR inhibition, providing a rationale for clinical exploration of DNA‐damage response inhibitors for PTCL treatment. A transplantable lymphoma arose in a Cγ1‐Cre Blimp1fl/fl mouse strain that is predisposed to spontaneous B‐cell hyperplasia.The lymphoma originated from a T‐cell progenitor and modelled cellular phenotypic hallmarks of human PTCL‐GATA3.A subset of human PTCL has activating mutations in β‐catenin. Similarly, a clonal Ctnnb1 1004A>C mutation encoding a K335T substitution in β‐catenin was found to have arisen spontaneously in the mouse lymphoma.mPTCL exhibited upregulation of β‐catenin and the downstream target Myc, together with biomarkers of DNA replication stress, and responded to the ATR inhibitor ceralasertib in vivo.Ceralasertib reduced proliferation of human PTCL cell lines, supporting a rationale for future clinical exploration of ATR inhibitors for the treatment of PTCL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
265. 63rd Annual Meeting of the Austrian Society of Surgery.
- Published
- 2022
- Full Text
- View/download PDF
266. Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice.
- Author
-
Kiesel, Brian F., Deppas, Joshua J., Guo, Jianxia, Parise, Robert. A., Clump, David A., Bakkenist, Christopher J., and Beumer, Jan H.
- Subjects
BIOAVAILABILITY ,ATAXIA telangiectasia ,DNA repair ,MICE ,BONE marrow ,DNA damage ,TISSUES - Abstract
Purpose: Ataxia Telangiectasia and Rad3-related (ATR) is a pivotal component of the DNA damage response and repair pathways that is activated in responses to cytotoxic cancer treatments. Several ATR inhibitors (ATRi) are in development that block the ATR mediated DNA repair and enhance the damage associated with cytotoxic therapy. BAY-1895344 (elimusertib) is an orally available ATRi with preclinical efficacy that is in clinical development. Little is known about the pharmacokinetics (PK) which is of interest, because tissue exposure and ATR inhibition may relate to toxicities or responses. Methods: To evaluate BAY-1895344 PK, a sensitive LC–MS/MS method was utilized for quantitation in mouse plasma and tissues. PK studies in mice were first conducted to determine dose linearity. In vivo metabolites were identified and analyzed semi-quantitatively. A compartmental PK model was developed to describe PK behavior. An extensive PK study was then conducted in tumor-bearing mice to quantitate tissue distribution for relevant tissues. Results: Dose linearity was observed from 1 to 10 mg/kg PO, while at 40 mg/kg PO bioavailability increased approximately fourfold due to saturation of first-pass metabolism, as suggested by metabolite analyses and a developed compartmental model. Longer half-lives in PO treated mice compared to IV treated mice indicated absorption-rate limited elimination. Tissue distribution varied but showed extensive distribution to bone marrow, brain, and spinal cord. Conclusions: Complex PK behavior was limited to absorption processes which may not be recapitulated clinically. Tissue partition coefficients may be used to contrast ATR inhibitors with respect to their efficacy and toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
267. The utility of cfDNA in TGCT patient management: a systematic review.
- Author
-
Krasic, Jure, Skara, Lucija, Bojanac, Ana Katusic, Ulamec, Monika, Jezek, Davor, Kulis, Tomislav, and Sincic, Nino
- Abstract
Background: Testicular germ cell tumors (TGCTs) are the most common young male malignancy with a steadily rising incidence. Standard clinical practice is radical orchidectomy of suspicious lumps followed by histopathological diagnosis and tumor subtyping. This practice can lead to complications and quality of life issues for the patients. Liquid biopsies, especially cell-free DNA (cfDNA), promised to be true surrogates for tissue biopsies, which are considered dangerous to perform in cases of testicular tumors. In this study, we have performed a systematic review on the potential of cfDNA in TGCT patient management, its potential challenges in translation to clinical application and possible approaches in further research. Materials & Methods: The review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines on EuropePMC and PUBMED electronic databases, with the last update being on October 21, 2021. Due to the high heterogeneity in identified research articles, we have performed an overview of their efficacy. Results: Eight original articles have been identified on cfDNA in TGCT patients published from 2004 to 2021, of which six had more than one TGCT patient enrolled and were included in the final analysis. Three studies investigated cfDNA methylation, one has investigated mutations in cfDNA, two have investigated cfDNA amount, and one has investigated cfDNA integrity in TGCT. The sensitivity of cfDNA for TGCT was found to be higher than in serum tumor markers and lower than miR-371a-3p, with comparable specificity. cfDNA methylation analysis has managed to accurately detect teratoma in TGCT patients. Conclusion: Potential challenges in cfDNA application to TGCT patient management were identified. The challenges relating to the biology of TGCT with its low mutational burden and low cfDNA amounts in blood plasma make next-generation sequencing (NGS) methods especially challenging. We have also proposed possible approaches to help find clinical application, including a focus on cfDNA methylation analysis, and potentially solving the challenge of teratoma detection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
268. Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France).
- Author
-
Ilié, Marius, Hofman, Véronique, Bontoux, Christophe, Heeke, Simon, Lespinet-Fabre, Virginie, Bordone, Olivier, Lassalle, Sandra, Lalvée, Salomé, Tanga, Virginie, Allegra, Maryline, Salah, Myriam, Bohly, Doriane, Benzaquen, Jonathan, Marquette, Charles-Hugo, Long-Mira, Elodie, and Hofman, Paul
- Subjects
LUNG cancer diagnosis ,SEQUENCE analysis ,WORKFLOW ,GENOMICS ,TURNAROUND time - Abstract
Simple Summary: Due to the increase of molecular biomarkers to be characterized to tailor therapeutic strategies for non-squamous non-small cell lung carcinoma (NS-NSCLC), it is now more and more challenging to evaluate these biomarkers using sequential analyses. We report here our experience concerning the development of an optimal workflow for genomic alteration assessment as reflex testing in routine clinical practice at diagnosis for NS-NSCLC patients by using an ultra-fast-next generation sequencing (NGS) approach. The analytical validation of the NGS workflow demonstrated 100% concordance with the gold standard methods. Only few cases failed for DNA/RNA NGS results. The mean turnaround time (TAT) was 72 h (ranging from 48 to 96 h). An ultra-fast NGS technique can maximize the management of the sample workflow in thoracic oncology to obtain the molecular biology results in an appropriate TAT, even when only a small amount of nucleic acids is available. The number of genomic alterations required for targeted therapy of non-squamous non-small cell lung cancer (NS-NSCLC) patients has increased and become more complex these last few years. These molecular abnormalities lead to treatment that provides improvement in overall survival for certain patients. However, these treated tumors inexorably develop mechanisms of resistance, some of which can be targeted with new therapies. The characterization of the genomic alterations needs to be performed in a short turnaround time (TAT), as indicated by the international guidelines. The origin of the tissue biopsies used for the analyses is diverse, but their size is progressively decreasing due to the development of less invasive methods. In this respect, the pathologists are facing a number of different challenges requiring them to set up efficient molecular technologies while maintaining a strategy that allows rapid diagnosis. We report here our experience concerning the development of an optimal workflow for genomic alteration assessment as reflex testing in routine clinical practice at diagnosis for NS-NSCLC patients by using an ultra-fast-next generation sequencing approach (Ion Torrent Genexus Sequencer, Thermo Fisher Scientific). We show that the molecular targets currently available to personalized medicine in thoracic oncology can be identified using this system in an appropriate TAT, notably when only a small amount of nucleic acids is available. We discuss the new challenges and the perspectives of using such an ultra-fast NGS in daily practice. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
269. Current and Developing Liquid Biopsy Techniques for Breast Cancer.
- Author
-
Wu, Hsing-Ju and Chu, Pei-Yi
- Subjects
BREAST tumor diagnosis ,MICRORNA ,RAMAN spectroscopy ,MESSENGER RNA ,BODY fluid examination ,TUMOR markers ,EXTRACELLULAR space ,NUCLEIC acids ,EXTRACELLULAR vesicles - Abstract
Simple Summary: Breast cancer is the most common cancer and leading cause of death worldwide. Therefore, it is important to diagnose and treat breast cancer early. Current diagnostic methods include mammography and tissue biopsy; however, they have limitations. Liquid biopsy is a less invasive tool for diagnosis. In this review, we summarize and focus on the recent discoveries on liquid biopsy and development of detection techniques. Breast cancer is the most commonly diagnosed cancer and leading cause of cancer mortality among woman worldwide. The techniques of diagnosis, prognosis, and therapy monitoring of breast cancer are critical. Current diagnostic techniques are mammography and tissue biopsy; however, they have limitations. With the development of novel techniques, such as personalized medicine and genetic profiling, liquid biopsy is emerging as the less invasive tool for diagnosing and monitoring breast cancer. Liquid biopsy is performed by sampling biofluids and extracting tumor components, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free mRNA (cfRNA) and microRNA (miRNA), proteins, and extracellular vehicles (EVs). In this review, we summarize and focus on the recent discoveries of tumor components and biomarkers applied in liquid biopsy and novel development of detection techniques, such as surface-enhanced Raman spectroscopy (SERS) and microfluidic devices. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
270. Immunometabolic Markers in a Small Patient Cohort Undergoing Immunotherapy.
- Author
-
Hofbauer, Joshua, Hauck, Andreas, Matos, Carina, Babl, Nathalie, Decking, Sonja-Maria, Rechenmacher, Michael, Schulz, Christian, Regotta, Sabine, Mickler, Marion, Haferkamp, Sebastian, Siska, Peter J., Herr, Wolfgang, Renner, Kathrin, Kreutz, Marina, and Schnell, Annette
- Subjects
LYMPHOCYTE count ,IMMUNE checkpoint proteins ,IMMUNOTHERAPY ,BIOMARKERS ,STATISTICAL correlation ,LYMPHOCYTE subsets - Abstract
Although the discovery of immune checkpoints was hailed as a major breakthrough in cancer therapy, generating a sufficient response to immunotherapy is still limited. Thus, the objective of this exploratory, hypothesis-generating study was to identify potentially novel peripheral biomarkers and discuss the possible predictive relevance of combining scarcely investigated metabolic and hormonal markers with immune subsets. Sixteen markers that differed significantly between responders and non-responders were identified. In a further step, the correlation with progression-free survival (PFS) and false discovery correction (Benjamini and Hochberg) revealed potential predictive roles for the immune subset absolute lymphocyte count (rs = 0.51; p = 0.0224 *), absolute basophil count (rs = 0.43; p = 0.04 *), PD-1+ monocytes (rs = −0.49; p = 0.04 *), hemoglobin (rs = 0.44; p = 0.04 *), metabolic markers LDL (rs = 0.53; p = 0.0224 *), free androgen index (rs = 0.57; p = 0.0224 *) and CRP (rs = −0.46; p = 0.0352 *). The absolute lymphocyte count, LDL and free androgen index were the most significant individual markers, and combining the immune subsets with the metabolic markers into a biomarker ratio enhanced correlation with PFS (rs = −0.74; p ≤ 0.0001 ****). In summary, in addition to well-established markers, we identified PD-1+ monocytes and the free androgen index as potentially novel peripheral markers in the context of immunotherapy. Furthermore, the combination of immune subsets with metabolic and hormonal markers may have the potential to enhance the power of future predictive scores and should, therefore, be investigated further in larger trials. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
271. Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics.
- Author
-
Le, Ilene, Dhandayuthapani, Subramanian, Chacon, Jessica, Eiring, Anna M., and Gadad, Shrikanth S.
- Subjects
CANCER vaccines ,CELL surface antigens ,IMMUNE system ,THERAPEUTICS ,PEPTIDES ,EMERGING infectious diseases - Abstract
Prophylactic vaccination against infectious diseases is one of the most successful public health measures of our lifetime. More recently, therapeutic vaccination against established diseases such as cancer has proven to be more challenging. In the host, cancer cells evade immunologic regulation by multiple means, including altering the antigens expressed on their cell surface or recruiting inflammatory cells that repress immune surveillance. Nevertheless, recent clinical data suggest that two classes of antigens show efficacy for the development of anticancer vaccines: tumor-associated antigens and neoantigens. In addition, many different vaccines derived from antigens based on cellular, peptide/protein, and genomic components are in development to establish their efficacy in cancer therapy. Some vaccines have shown promising results, which may lead to favorable outcomes when combined with standard therapeutic approaches. This review provides an overview of the innate and adaptive immune systems, their interactions with cancer cells, and the development of various different vaccines for use in anticancer therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
272. ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications.
- Author
-
Jabbour, Tony El, Misyura, Maksym, Cowzer, Darren, Zimmermann, Michal, Rimkunas, Victoria, Marra, Antonio, Derakhshan, Fatemeh, Selenica, Pier, Parilla, Megan, Setton, Jeremy S, Ceyhan-Birsoy, Ozge, Kemel, Yelena, Catchings, Amanda, Ranganathan, Megha, Ku, Geoffrey Y, Janjigian, Yelena Y, Zinda, Michael, Koehler, Maria, Stadler, Zsofia, and Shia, Jinru
- Subjects
STOMACH tumors ,ADENOCARCINOMA ,ESOPHAGUS ,PROTEIN kinases ,GERM cells ,RESEARCH funding ,ESOPHAGEAL tumors - Abstract
Background: Gastroesophageal junction (GEJ) adenocarcinoma is a rare cancer associated with poor prognosis. The genetic factors conferring predisposition to GEJ adenocarcinoma have yet to be identified.Methods: We analyzed germline testing results from 23 381 cancer patients undergoing tumor-normal sequencing, of which 312 individuals had GEJ adenocarcinoma. Genomic profiles and clinico-pathologic features were analyzed for the GEJ adenocarcinomas. Silencing of ATM and ATR was performed using validated short-interfering RNA species in GEJ, esophageal, and gastric adenocarcinoma cell lines. All statistical tests were 2-sided.Results: Pathogenic or likely pathogenic ATM variants were identified in 18 of 312 patients (5.8%), and bi-allelic inactivation of ATM through loss of heterozygosity of the wild-type allele was detected in all (16 of 16) samples with sufficient tumor content. Germline ATM-mutated GEJ adenocarcinomas largely lacked somatic mutations in TP53, were more likely to harbor MDM2 amplification, and harbored statistically significantly fewer somatic single nucleotide variants (2.0 mutations/Mb vs 7.9 mutations/Mb; P < .001). A statistically significantly higher proportion of germline ATM-mutated than ATM-wild-type GEJ adenocarcinoma patients underwent a curative resection (10 [100%] vs 92 [86.8%], P = .04; Fisher's exact test.), A synthetic lethal interaction between short-interfering RNA silencing of ATM and ATR was observed in the models analyzed.Conclusions: Our results indicate that germline pathogenic variants in ATM drive oncogenesis in GEJ adenocarcinoma and might result in a distinct clinical phenotype. Given the high prevalence of germline ATM-mutated GEJ adenocarcinomas, genetic testing for individuals with GEJ adenocarcinomas may be considered to better inform prognostication, treatment decisions, and future cancer risk. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
273. ERGEBNISSE DER ZISTERZIENSER-FORSCHUNG IN NORDOSTDEUTSCHLAND SEIT 1998.
- Author
-
Pötschke, Dieter
- Published
- 2022
274. Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR).
- Author
-
Wang, Li-Wei, Jiang, Songwei, Yuan, Ying-Hui, Duan, Jilong, Mao, Nian-Dong, Hui, Zi, Bai, Renren, Xie, Tian, and Ye, Xiang-Yang
- Subjects
ATAXIA telangiectasia ,PROTEIN kinases ,DNA damage ,ANTINEOPLASTIC agents ,PSEUDOPOTENTIAL method - Abstract
As one of the key phosphatidylinositol 3-kinase-related kinases (PIKKs) family members, ataxia telangiectasia and RAD3-related protein kinase (ATR) is crucial in maintaining mammalian cell genomic integrity in DNA damage response (DDR) and repair pathways. Dysregulation of ATR has been found across different cancer types. In recent years, the inhibition of ATR has been proven to be effective in cancer therapy in preclinical and clinical studies. Importantly, tumor-specific alterations such as ATM loss and Cyclin E1 (CCNE1) amplification are more sensitive to ATR inhibition and are being exploited in synthetic lethality (SL) strategy. Besides SL, synergistic anticancer effects involving ATRi have been reported in an increasing number in recent years. This review focuses on the recent advances in different forms of synergistic antitumor effects, summarizes the pharmacological benefits and ongoing clinical trials behind the biological mechanism, and provides perspectives for future challenges and opportunities. The hope is to draw awareness to the community that targeting ATR should have great potential in developing effective anticancer medicines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
275. Testicular Germ Cell Tumours and Proprotein Convertases.
- Author
-
Velado-Eguskiza, Aitziber, Gomez-Santos, Laura, Badiola, Iker, Sáez, Francisco José, and Alonso, Edurne
- Subjects
GERM cell tumors ,MEN'S health ,PROTEOLYTIC enzymes ,TREATMENT effectiveness ,TESTIS tumors ,TUMOR markers ,IMMUNOTHERAPY ,SEMINOMA - Abstract
Simple Summary: Despite the high survival rate of the most common neoplasia in young Caucasian men: Testicular Germ Cell Tumors (TGCT), the quality of life of these patients is impaired by the multiple long-term side effects of their treatment. The study of molecules that can serve both as diagnostic biomarkers for tumor development and as therapeutic targets seems necessary. Proprotein convertases (PC) are a group of proteases responsible for the maturation of inactive proproteins with very diverse functions, whose alterations in expression have been associated with various diseases, such as other types of cancer and inflammation. The study of the immune tumor microenvironment and the substrates of PCs could contribute to the development of new and necessary immunotherapies to treat this pathology. Testicular Germ Cell Tumours (TGCT) are widely considered a "curable cancer" due to their exceptionally high survival rate, even if it is reduced by many years after the diagnosis due to metastases and relapses. The most common therapeutic approach to TGCTs has not changed in the last 50 years despite its multiple long-term side effects, and because it is the most common malignancy in young Caucasian men, much research is needed to better the quality of life of the many survivors. Proprotein Convertases (PC) are nine serine proteases responsible for the maturation of inactive proproteins with many diverse functions. Alterations in their expression have been associated with various diseases, including cancer and inflammation. Many of their substrates are adhesion molecules, metalloproteases and proinflammatory molecules, all of which are involved in tumour development. Inhibition of certain convertases has also been shown to slow tumour formation, demonstrating their involvement in this process. Considering the very established link between PCs and inflammation-related malignancies and the recent studies carried out into the immune microenvironment of TGCTs, the study of the involvement of PCs in testicular cancer may open up avenues for being both a biomarker for diagnosis and a therapeutic target. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
276. Structural Insights from Molecular Modeling of Isoindolin-1-One Derivatives as PI3Kγ Inhibitors against Gastric Carcinoma.
- Author
-
Ghosh, Suparna and Cho, Seung Joo
- Subjects
STOMACH cancer ,TUMOR necrosis factors ,COMPARATIVE molecular field analysis ,STRUCTURE-activity relationships ,BINDING energy - Abstract
The upregulation of phosphoinositol-3-kinase γ (PI3Kγ) is deemed to be positively correlated with tumor-associated-macrophage (TAM)-mediated gastric carcinoma (GC). PI3Kγ suppresses tumor necrosis factor-alpha (TNF-α) and interleukin-12 (IL-12) through activation of the AKT/mTOR pathway, which promotes the immunosuppressant phenotype of TAM. Unlike α and β isoforms, δ and γ isoforms are primarily distributed in leucocytes and macrophages. Dual inhibitors against PI3Kδ and PI3Kγ have been proven to have merits in targeting solid tumors. Furthermore, it has been found that PI3Kδ is activated by cytokines, while PI3Kγ is activated by G-protein-coupled receptors (GPCRs). This facilitates determining the functional difference between these two isoforms. For this goal, selective inhibitors would be immensely helpful. In the current manuscript, we conducted various molecular modeling studies with a series of isoindolin-1-one derivatives as potent PI3Kγ inhibitors by combining molecular docking, molecular dynamics (MD), molecular mechanics, Poisson–Boltzmann/generalized Born surface area (MM-PB/GBSA) binding free energy calculation, and three-dimensional structure–activity relationship (3D-QSAR) study. To evaluate the selectivity of γ isoform over δ, the molecular modeling studies of idelalisib analogs reported as PI3Kδ inhibitors were also investigated. The contour polyhedrons were generated from the comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) around the ligand-bound active site for both isoforms, which could emphasize plausible explanations for the physicochemical factors that affect selective ligand recognition. The binding modalities of the two isoforms using CoMFA and MD models were compared, which suggested some key differences in the molecular interactions with the ligands and could be summarized as three subsites (one affinity subsite near the C-helix and DFG and two hydrophobic subsites). In the context of the structure–activity relationship (SAR), several new compounds were designed using a fragment-substitution strategy with the aim of selectively targeting PI3Kγ. The pIC
50 values of the designed compounds were predicted by the 3D-QSAR models, followed by the MM-PB/GBSA binding energy estimation. The overall findings suggest that the designed compounds have the potential to be used as PI3Kγ inhibitors with a higher binding affinity and selectivity. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
277. DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directions.
- Author
-
Chen, Tianen, Tongpeng, Suparat, Lu, Ziyi, Topatana, Win, Juengpanich, Sarun, Li, Shijie, Hu, Jiahao, Cao, Jiasheng, Lee, Cheeshin, Tian, Yitong, Chen, Mingyu, and Cai, Xiujun
- Published
- 2022
- Full Text
- View/download PDF
278. Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
- Author
-
Suppan, Christoph, Graf, Ricarda, Jahn, Stephan, Zhou, Qing, Klocker, Eva Valentina, Bartsch, Rupert, Terbuch, Angelika, Kashofer, Karl, Regitnig, Peter, Lindenmann, Joerg, Posch, Florian, Gerritsmann, Hanno, Jost, Philipp J., Heitzer, Ellen, Dandachi, Nadia, and Balic, Marija
- Abstract
Background: The benefit of alpelisib in hormone-receptor-positive (HR+) metastatic breast cancer patients provided clinical evidence for the increasing importance of PIK3CA testing. We performed a comparison of liquid biopsy and tissue-based detection of PIK3CA mutations. Materials and methods: PIK3CA hotspot mutation analysis using a high-resolution SiMSen-Seq assay was performed in plasma from 93/99 eligible patients with HR+/HER2− breast cancer. Additionally, mFAST-SeqS was used to estimate the tumour fractions in plasma samples. In 72/93 patients, matched tissue was available and analysed using a customised Ion Torrent panel. Results: PIK3CA mutations were detected in 48.6% of tissue samples and 47.3% of plasma samples, with identical PIK3CA mutation detected in 24/72 (33.3%) patients both in tissue and plasma. In 10 (13.9%) patients, mutations were only found in plasma, and in 6 (8.3%) patients, PIK3CA mutations found in tissue were not detectable in ctDNA. In 49/93 plasma samples without detectable PIK3CA mutations, 22 (44.9%) samples had elevated tumour fractions, implying true negative results. Conclusion: SiMSen-Seq-based detection of PIK3CA mutations in plasma shows advantageous concordance with the tissue analyses. A combination with an untargeted approach for detecting ctDNA fractions may confirm a negative PIK3CA result and enhance the performance of the SiMSen-Seq test. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
279. الأسس المنهجية لتحرير المعجم التاريخي للغة العربية.
- Author
-
المعتز بالله الس
- Subjects
ENCYCLOPEDIAS & dictionaries ,HISTORIC buildings ,POWER resources ,LEXICOGRAPHY ,ARABS - Abstract
Copyright of Annals of Arts & Social Sciences / Hawliyyat Kulliyyat al-adab is the property of Kuwait University, Academic Publication Council and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
280. Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer.
- Author
-
Shiota, Masaki, Fujimoto, Naohiro, Sekino, Yohei, Tsukahara, Shigehiro, Nagakawa, Shohei, Takamatsu, Dai, Abe, Tatsuro, Kinoshita, Fumio, Ueda, Shohei, Ushijima, Miho, Matsumoto, Takashi, Kashiwagi, Eiji, Inokuchi, Junichi, Uchiumi, Takeshi, Oda, Yoshinao, and Eto, Masatoshi
- Subjects
PROSTATE cancer ,CASTRATION-resistant prostate cancer ,PROSTATE cancer patients ,METASTASIS ,SOMATIC mutation ,GENE expression - Abstract
This study aimed to investigate the significance of HSD3B1 gene status including germline polymorphism and somatic alterations in prostate cancer. Patients with prostate cancer treated with androgen‐deprivation therapy, as well as tissues from metastatic prostate cancer, were included. Genomic DNA was extracted from cancer tissues and whole blood samples, and HSD3B1 (rs1047303, 1245C) was genotyped by Sanger sequencing. The association of HSD3B1 genotype with progression‐free survival according to metastatic volume was examined. Copy number alteration and gene expression of HSD3B1 were examined in prostate cancer cells and public datasets. Among 194 patients, 121 and 73 patients were categorized into low‐ and high‐volume diseases respectively. In multivariate analysis, the adrenal‐permissive genotype (AC/CC) was significantly associated with increased risk of progression compared with the adrenal‐restrictive genotype (AA) in low volume, but not high‐volume diseases. Somatic mutation in HSD3B1 was detected at least in two cases of castration‐resistant prostate cancer tissues. HSD3B1 amplification and overexpression were detected in castration‐resistant prostate cancer cells and tissues. The current findings suggest that both germline and somatic alterations of HSD3B1 may cooperatively promote castration resistance in prostate cancer and HSD3B1 as a promising biomarker for precision medicine, warranting further investigations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
281. Irreversibility of Pulmonary Fibrosis.
- Author
-
Qing Yang Yu and Xiao Xiao Tang
- Subjects
PULMONARY fibrosis ,EXTRACELLULAR matrix ,WOUND healing - Abstract
Pulmonary fibrosis, a kind of terminal pathological changes in the lung, is caused by aberrant wound healing, deposition of extracellular matrix (ECM), and eventually replacement of lung parenchyma by ECM. Pulmonary fibrosis induced by acute lung injury and some diseases is reversible under treatment. While idiopathic pulmonary fibrosis is persistent and irreversible even after treatment. Currently, the pathogenesis of irreversible pulmonary fibrosis is not fully elucidated. The known factors associated with the development of irreversible fibrosis include apoptosis resistance of (myo)fibroblasts, dysfunction of pulmonary vessel, cell mitochondria and autophagy, aberrant epithelia hyperplasia and lipid metabolism disorder. In this review, other than a brief introduction of reversible pulmonary fibrosis, we focus on the underlying pathogenesis of irreversible pulmonary fibrosis from the above aspects as well as preclinical disease models, and also suggest directions for future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
282. A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer.
- Author
-
Westaby, Daniel, Fenor de La Maza, Maria de Los Dolores, Paschalis, Alec, Jimenez-Vacas, Juan M., Welti, Jon, de Bono, Johann, and Sharp, Adam
- Subjects
PROSTATE tumors treatment ,CELL receptors ,CELLULAR signal transduction ,ANDROGEN receptors ,DRUG resistance in cancer cells - Abstract
Owing to the development of multiple novel therapies, there has been major progress in the treatment of advanced prostate cancer over the last two decades; however, the disease remains invariably fatal. Androgens and the androgen receptor (AR) play a critical role in prostate carcinogenesis, and targeting the AR signaling axis with abiraterone, enzalutamide, darolutamide, and apalutamide has improved outcomes for men with this lethal disease. Targeting the AR and elucidating mechanisms of resistance to these agents remain central to drug development efforts. This review provides an overview of the evolution and current approaches for targeting the AR in advanced prostate cancer. It describes the biology of AR signaling, explores AR-targeting resistance mechanisms, and discusses future perspectives and promising novel therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
283. Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden.
- Author
-
Fallara, Giuseppe, Alverbratt, Charlotte, Garmo, Hans, Vikman, Hanna, Hjelm Eriksson, Marie, Lissbrant, Ingela Franck, and Stattin, Pär
- Subjects
ANTIANDROGENS ,ACQUISITION of data methodology ,CONFIDENCE intervals ,ABIRATERONE acetate ,REGRESSION analysis ,CANCER patients ,TREATMENT effectiveness ,MEDICAL records ,KAPLAN-Meier estimator ,PROSTATE tumors ,PROPORTIONAL hazards models ,CLINICAL trial registries ,PHARMACODYNAMICS - Abstract
There are little and inconsistent data from clinical practice on time on treatment with the androgen receptor-targeted drugs (ART) abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC). We assessed time on treatment with ART and investigated predictors of time on treatment. Time on treatment with ART in men with mCRPC in the patient-overview prostate cancer (PPC), a subregister of the National Prostate Cancer Register (NPCR) of Sweden, was assessed by use of Kaplan–Meier plots and Cox regression. To assess the representativity of PPC for time on treatment, a comparison was made with all men in NPCR who had a filling for ART in the Prescribed Drug Registry. 2038 men in PPC received ART between 2015 and 2019. Median time on treatment in chemo-naïve men was 10.8 (95% confidence interval 9.1–13.1) months for abiraterone and 14.1 (13.5–15.5) for enzalutamide. After the use of docetaxel, time on treatment was 8.2 (6.5–12.4) months for abiraterone and 11.1 (9.8–12.6) for enzalutamide. Predictors of a long time on treatment with ART were long duration of ADT prior to ART, low serum levels of PSA at start of ART, absence of visceral metastasis, good performance status, and no prior use of docetaxel. PPC captured 2522/6337 (40%) of all men in NPCR who had filled a prescription for ART. Based on fillings in the Prescribed Drug Registry, men in PPC had a slightly longer median time on treatment with ART compared to all men in NPCR, 9.6 (9.1–10.3) vs. 8.6 (6.3–9.1) months. Time on treatment in clinical practice was similar or shorter than that in published RCTs, due to older age, poorer performance status and more comorbidities. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
284. La gestione delle tossicità polmonari indotte dalla terapia target e dalla immunoterapia nel carcinoma polmonare: ruolo dello pneumologo.
- Author
-
Bonti, Viola and Ferrari, Katia
- Abstract
Copyright of Rassegna di Patologia dell'Apparato Respiratorio is the property of AIPO - Associazione Italiana Pneumologi Ospedalieri and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
- Full Text
- View/download PDF
285. Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high‐dose chemotherapy and peripheral blood stem cell transplantation.
- Author
-
Agrawal, Vaibhav, Abonour, Rafat, Abu Zaid, Mohammad, Althouse, Sandra K., Ashkar, Ryan, Albany, Costantine, Hanna, Nasser H., Einhorn, Lawrence H., and Adra, Nabil
- Subjects
SURVIVAL rate ,STEM cell transplantation ,TREATMENT effectiveness ,BLOOD cells ,TESTICULAR cancer ,OVERALL survival ,GERM cell tumors - Abstract
BACKGROUND: High‐dose chemotherapy (HDCT) plus peripheral blood stem cell transplantation (PBSCT) is effective salvage therapy for relapsed metastatic germ cell tumors (GCTs) but has potential toxicity. Historically, an age of ≥40 years has been associated with greater toxicity and worse outcomes. METHODS: This is a retrospective analysis of 445 consecutive patients with relapsed GCT treated with HDCT and PBSCT with tandem cycles at Indiana University from between 2004‐2017 per our institutional regimen. Kaplan‐Meier methods and log‐rank tests were used for progression‐free survival (PFS) and overall survival (OS) analysis. RESULTS: A total of 329 patients were <40 years of age, whereas 116 patients were ≥40 years of age; HDCT was used as second‐line therapy in 85% and 79%, respectively. Median follow‐up time was 42.5 months (range, 0.3‐173.4 months). Grade ≥3 toxicities were similar between either group, except for greater pulmonary (P =.02) and renal toxicity (P =.01) in the ≥40‐years‐of‐age group. Treatment‐related mortality was similar between both age groups: 10 patients (3%) in the <40‐years‐of‐age group and 4 patients (3.5%) in ≥40‐years‐of‐age group died from complications of HDCT. Two‐year PFS for <40 years of age versus ≥40 years of age was 58.7% versus 59.6% (P =.76) and 2‐year OS was 63.9% versus 61.5% (P =.93). Factors predicting worse PFS included Eastern Cooperative Oncology Group performance status ≥1, platinum refractory disease, nonseminoma histology, and not completing 2 cycles of HDCT. Age was not an independent predictor of worse outcomes. CONCLUSIONS: HDCT plus PBSCT is effective salvage therapy in patients ≥40 years of age with relapsed metastatic GCT. Patients ≥40 years of age experience similar rates of toxicity and treatment‐related mortality as those <40 years of age. High‐dose chemotherapy plus peripheral blood stem cell transplantation as salvage therapy for relapsed metastatic germ cell tumor is effective in older patients ≥40 years of age with 2‐year progression‐free survival and overall survival of 58.7% and 61.5%, respectively. Patients ≥40 years of age experience similar rates of toxicity and treatment‐related mortality as patients <40 years of age. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
286. Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells.
- Author
-
Li, Chengguo, Shen, Qian, Zhang, Peng, Wang, Tao, Liu, Weizhen, Li, Ruidong, Ma, Xianxiong, Zeng, Xiangyu, Yin, Yuping, and Tao, Kaixiong
- Subjects
IMMUNE checkpoint inhibitors ,ANTINEOPLASTIC agents ,STOMACH cancer ,CANCER cells ,IMMUNE checkpoint proteins ,IPILIMUMAB - Abstract
Background: Identification of genomic biomarkers to predict the anticancer effects of indicated drugs is considered a promising strategy for the development of precision medicine. DNA endonuclease MUS81 plays a pivotal role in various biological processes during malignant diseases, mainly in DNA damage repair and replication fork stability. Our previous study reported that MUS81 was highly expressed and linked to tumor metastasis in gastric cancer; however, its therapeutic value has not been fully elucidated. Methods: Bioinformatics analysis was used to define MUS81-related differential genes, which were further validated in clinical tissue samples. Gain or loss of function MUS81 cell models were constructed to elucidate the effect and mechanism of MUS81 on WEE1 expression. Moreover, the antitumor effect of targeting MUS81 combined with WEE1 inhibitors was verified using in vivo and in vitro assays. Thereafter, the cGAS/STING pathway was evaluated, and the therapeutic value of MUS81 for immunotherapy of gastric cancer was determined. Results: In this study, MUS81 negatively correlated with the expression of cell cycle checkpoint kinase WEE1. Furthermore, we identified that MUS81 regulated the ubiquitination of WEE1 via E-3 ligase β-TRCP in an enzymatic manner. In addition, MUS81 inhibition could sensitize the anticancer effect of the WEE1 inhibitor MK1775 in gastric cancer in vitro and in vivo. Interestingly, when MUS81 was targeted, it increased the accumulation of cytosolic DNA induced by MK1775 treatment and activated the DNA sensor STING-mediated innate immunity in the gastric cancer cells. Thus, the WEE1 inhibitor MK1775 specifically enhanced the anticancer effect of immune checkpoint blockade therapy in MUS81 deficient gastric cancer cells. Conclusions: Our data provide rational evidence that targeting MUS81 could elevate the expression of WEE1 by regulating its ubiquitination and could activate the innate immune response, thereby enhancing the anticancer efficacy of WEE1 inhibitor and immune checkpoint blockade combination therapy in gastric cancer cells. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
287. Digitale Gesamtedition und Übersetzung des koptisch-sahidischen Alten Testaments.
- Author
-
Behlmer, H.
- Published
- 2021
288. Abstracts des 73. Kongresses der Deutschen Gesellschaft für Urologie e. V.
- Published
- 2021
- Full Text
- View/download PDF
289. History of whole pelvis plus para-aortic radiation is a risk factor associated with febrile neutropenia during chemotherapy for recurrent cervical cancer.
- Author
-
Nara, Katsuhiko, Taguchi, Ayumi, Tojima, Yuri, Miyamoto, Yuichiro, Tanikawa, Michihiro, Sone, Kenbun, Mori, Mayuyo, Tsuruga, Tetsushi, Yamamoto, Takehito, Takenaka, Ryosuke, Takada, Tappei, Osuga, Yutaka, and Suzuki, Hiroshi
- Subjects
CERVICAL cancer ,FEBRILE neutropenia ,CANCER chemotherapy ,PELVIS ,RADIATION ,INDUCTIVE effect - Abstract
Background: Radiation-based therapy is widely used for advanced cervical cancer. Prior radiation-based therapy is a potential risk factor for febrile neutropenia (FN). However, the effect of irradiation field size on the incidence of FN during recurrent cervical cancer treatment is unclear. This study aimed to investigate the relationship between prior irradiation field size and FN development during recurrent chemotherapy. Methods: This retrospective, observational study included cervical cancer patients who received recurrent chemotherapy between November 2006 and June 2020. The patients were classified into two groups based on the area of irradiation fields. The first group included patients with a history of whole pelvis (WP) irradiation (WP group). The second group had patients who underwent WP plus para-aortic lymph node (PAN) irradiation (WP + PAN group). The incidences of hematological toxicities and FN during the recurrent chemoradiotherapy were compared between the two groups. Results: The FN incidence was significantly higher in the WP + PAN group than in the WP group (32.1% vs. 0%, P < 0.001). The incidence of Grade 4 neutropenia was not significantly different between the WP + PAN and WP groups. The nadir absolute neutrophil counts were significantly lower and the dose reduction or discontinuation rate of chemotherapy was significantly higher in the WP + PAN group than in the WP group. Conclusion: History of WP plus PAN radiation is a risk factor for developing FN during recurrent cervical cancer chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
290. Improving outcomes in germ cell cancers using miRNA.
- Author
-
Conduit, Ciara and Tran, Ben
- Abstract
Owing to advances in treatment paradigms across the last five decades, testicular cancer is now eminently curable. However, current serum tumour and imaging biomarkers lack adequate sensitivity, specificity, and predictive value. Subsequently, their utility in detecting active malignancy and informing treatment decisions is minimal in a large proportion of men with testicular cancer. Micro-ribonucleic acids (miRNA), pertinently miR-371a-3p, offer a new tool, which based on early data, appears to fill many of the gaps that existing biomarkers leave. This paper reviews the evolution of the technology, potential limitations, and discusses the clinical relevance of miRNA as it moves towards the clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
291. EINIGE NEUE BEMERKUNGEN ZUM ÄGYPTISCHEN WORT 'B "BOGEN".
- Author
-
Bojowald, Stefan
- Subjects
COMPOSITE construction ,VOCABULARY ,LANGUAGE & languages - Abstract
This article looks for a deeper understanding of the word 'b "bow." The derivation of the word from the root 'b "horn," suggested already by Gardiner, is related here to the importation of horns of the Cretan wild goat for the construction of composite bows. The word can thus be established as a technical term for the composite bow, perhaps borrowed from the military language. [ABSTRACT FROM AUTHOR]
- Published
- 2021
292. Hormonal Therapy for Prostate Cancer.
- Author
-
Desai, Kunal, McManus, Jeffrey M, and Sharifi, Nima
- Subjects
ANDROGEN receptors ,PROSTATE cancer ,HORMONE therapy ,CANCER treatment ,TESTOSTERONE ,LEUPROLIDE - Abstract
Huggins and Hodges demonstrated the therapeutic effect of gonadal testosterone deprivation in the 1940s and therefore firmly established the concept that prostate cancer is a highly androgen-dependent disease. Since that time, hormonal therapy has undergone iterative advancement, from the types of gonadal testosterone deprivation to modalities that block the generation of adrenal and other extragonadal androgens, to those that directly bind and inhibit the androgen receptor (AR). The clinical states of prostate cancer are the product of a superimposition of these therapies with nonmetastatic advanced prostate cancer, as well as frankly metastatic disease. Today's standard of care for advanced prostate cancer includes gonadotropin-releasing hormone agonists (e.g. leuprolide), second-generation nonsteroidal AR antagonists (enzalutamide, apalutamide, and darolutamide) and the androgen biosynthesis inhibitor abiraterone. The purpose of this review is to provide an assessment of hormonal therapies for the various clinical states of prostate cancer. The advancement of today's standard of care will require an accounting of an individual's androgen physiology that also has recently recognized germline determinants of peripheral androgen metabolism, which include HSD3B1 inheritance. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
293. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high‐risk localized prostate cancer.
- Author
-
Graham, Laura S., True, Lawrence D., Gulati, Roman, Schade, George R., Wright, Jonathan, Grivas, Petros, Yezefski, Todd, Nega, Katie, Alexander, Katerina, Hou, Wen‐Min, Yu, Evan Y., Montgomery, Bruce, Mostaghel, Elahe A., Matsumoto, Alvin A., Marck, Brett, Sharifi, Nima, Ellis, William J., Reder, Nicholas P., Lin, Daniel W., and Nelson, Peter S.
- Published
- 2021
- Full Text
- View/download PDF
294. Potential biomarkers for testicular germ cell tumour: Risk assessment, diagnostic, prognostic and monitoring of recurrence.
- Author
-
Lakpour, Niknam, Saliminejad, Kioomars, Ghods, Roya, Reza Sadeghi, Mohammad, Pilatz, Adrian, Khosravi, Farhad, and Madjd, Zahra
- Subjects
GERM cells ,EMBRYONIC stem cells ,RISK assessment ,BIOMARKERS ,DIAGNOSIS ,SPERMATIC cord torsion - Abstract
Testicular germ cell tumour (TGCT) is considered a relatively rare malignancy usually occurring in young men between 15 and 35 years of age, and both genetic and environmental factors contribute to its development. The majority of patients are diagnosed in an early‐stage of TGCTs with an elevated 5‐year survival rate after therapy. However, approximately 25% of patients show an incomplete response to chemotherapy or tumours relapse. The current therapies are accompanied by several adverse effects, including infertility. Aside from classical serum biomarker, many studies reported novel biomarkers for TGCTs, but without proper validation. Cancer cells share many similarities with embryonic stem cells (ESCs), and since ESC genes are not transcribed in most adult tissues, they could be considered ideal candidate targets for cancer‐specific diagnosis and treatment. Added to this, several microRNAs (miRNA) including miRNA‐371‐3p can be further investigated as a molecular biomarker for diagnosis and monitoring of TGCTs. In this review, we will illustrate the findings of recent investigations in novel TGCTs biomarkers applicable for risk assessment, screening, diagnosis, prognosis, prediction and monitoring of the relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
295. Characterization of progression-related alternative splicing events in testicular germ cell tumors.
- Author
-
Zhang, Chuan-Jie, Li, Zong-Tai, Shen, Kan-Jie, Chen, Lu, Xu, Dan-Feng, and Gao, Yi
- Abstract
Accumulating evidence supports the significance of aberrant alternative splicing (AS) events in cancer; however, genome-wide profiling of progression-free survival (PFS)-related AS events in testicular germ cell tumors (TGCT) has not been reported. Here, we analyzed high-throughput RNA-sequencing data and percent-spliced-in values for 150 patients with TGCT. Using univariate and multivariate Cox regression analysis and a least absolute shrinkage and selection operator method, we identified the top 15 AS events most closely associated with disease progression. A risk-associated AS score (ASS) for the 15 AS events was calculated for each patient. ASS, pathological stage, and T stage were significantly associated with disease progression by univariate analysis, but only ASS and pathological stage remained significant by multivariate analysis. The ability of these variables to predict 5-year progression was assessed using receiver operating characteristic curve analysis. ASS had stronger predictive value than a combination of age, pathological stage, and T stage (area under the curve = 0.899 and 0.715, respectively). Furthermore, Kaplan–Meier analysis of patients with low and high ASS demonstrated that high ASS was associated with significantly worse PFS than low ASS (P = 1.46 × 10
−7 ). We also analyzed the biological functions of the PFS-related AS-related genes and found enrichment in pathways associated with DNA repair and modification. Finally, we identified a regulatory network of splicing factors with expression levels that correlated significantly with AS events in TGCT. Collectively, this study identifies a novel method for risk stratification of patients and provides insight into the molecular events underlying TGCT. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
296. Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer Outcomes.
- Author
-
McKay, Rana R., Nelson, Tyler J., Pagadala, Meghana S., Teerlink, Craig C., Gao, Anthony, Bryant, Alex K., Agiri, Fatai Y., Guram, Kripa, Thompson, Reid F., Pridgen, Kathryn M., Seibert, Tyler M., Lee, Kyung Min, Carter, Hannah, Lynch, Julie A., Hauger, Richard L., and Rose, Brent S.
- Published
- 2024
- Full Text
- View/download PDF
297. 약물유발 사이질폐질환의 진단과 치료.
- Author
-
박 상 훈 and 이 은 주
- Subjects
THERAPEUTICS ,IMMUNE checkpoint inhibitors ,ADRENOCORTICAL hormones ,EPIDERMAL growth factor receptors ,INTERSTITIAL lung diseases ,AMIODARONE ,BLEOMYCIN ,IMMUNOTHERAPY - Abstract
Drug-induced interstitial lung disease (DILD) is a group of adverse drug reactions that is rare but fatally toxic. Pulmonary toxicity causes inflammation and subsequent interstitial fibrosis. As novel drugs with a variety of purposes are introduced into the medical field, the number of culprit medications that are suspected to cause lung complications is accordingly increasing. In this review, DILD will be discussed from several aspects such as causality by numerous drugs, check points for a timely diagnosis, alongside some contemporary treatment options. The exact mechanism of DILD has not been elucidated, and a useful clinical, radiological, or pathological confirmation process is still lacking. Common drugs which casue DILD include bleomycin, amiodarone, epidermal growth factor receptor-targeted agents, and immune checkpoint inhibitors. Diagnosis is based on a suspicious drug administration history, somewhat inconsistent clinical symptoms and signs, radiological hints, and histopathological assistance, together with the exclusion of other lung-injuring etiologies. Cessation of the suspected drug, meticulous corticosteroid usage, and ancillary supportive management are the mainstay therapeutic strategy for DILD. Most cases of DILD respond to these countermeasures and reductions, but in some cases the fibrotic process worsens, leading to irreversible sequelae on the affected lung. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
298. RNA-Binding Proteins Play an Important Role in the Prognosis of Patients With Testicular Germ Cell Tumor.
- Author
-
Yao, Liangyu, Cong, Rong, Ji, Chengjian, Zhou, Xiang, Luan, Jiaochen, Meng, Xianghu, and Song, Ninghong
- Subjects
GERM cell tumors ,RNA-binding proteins ,NOMOGRAPHY (Mathematics) ,RECEIVER operating characteristic curves ,PROGNOSIS ,PROGNOSTIC models ,PROGRESSION-free survival - Abstract
Testicular germ cell tumors (TGCTs) are common urological neoplasms in young adult males. The outcome of TGCT depends on pathologic type and tumor stage. RNA-binding proteins (RBPs) influence numerous cancers via post-transcriptional regulation. The prognostic importance of RBPs in TGCT has not been fully investigated. In this study, we set up a prognostic risk model of TGCT using six significantly differentially expressed RBPs, namely, TRMT61A, POLR2J, DIS3L2, IFIH1, IGHMBP2 , and NPM2. The expression profiles were downloaded from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression datasets. We observed by performing least absolute shrinkage and selection operator (LASSO) regression analyses that in the training cohort, the expression of six RBPs was correlated with disease-free survival in patients with TGCT. We assessed the specificity and sensitivity of 1-, 3-, 5-, and 10-year survival status prediction using receiver operating characteristic curve analysis and successfully validated using the test cohorts, the entire TCGA cohort, and Gene Expression Omnibus (GEO) datasets. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and gene set enrichment analyses were carried out to seek the possible signaling pathways related with risk score. We also examined the association between the model based on six RBPs and different clinical characteristics. A nomogram was established for TGCT recurrence prediction. Consensus clustering analysis was carried out to identify the clusters of TGCT with different clinical outcomes. Ultimately, external validations of the six-gene risk score were performed by using the GSE3218 and GSE10783 datasets downloaded from the GEO database. In general, our study constructed a prognostic model based on six RBPs, which could serve as independent risk factor in TGCT, especially in seminoma, and might have brilliant clinical application value. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
299. The detection of isochromosome i(12p) in malignant germ cell tumours and tumours with somatic malignant transformation by the use of quantitative real‐time polymerase chain reaction.
- Author
-
Fichtner, Alexander, Richter, Annika, Filmar, Simon, Gaisa, Nadine T, Schweyer, Stefan, Reis, Henning, Nettersheim, Daniel, Oing, Christoph, Gayer, Fabian A, Leha, Andreas, Küffer, Stefan, Ströbel, Philipp, Kaulfuß, Silke, and Bremmer, Felix
- Subjects
POLYMERASE chain reaction ,GERM cells ,PLANT chromosomes ,ALKANES ,TUMORS - Abstract
Aims: Malignant germ cell tumours (GCTs) of the testis are rare neoplasms, but the most common solid malignancies in young men. World Health Organization guidelines divide GCTs into five types, for which numerous immunohistochemical markers allow exact histological subtyping in the majority of cases. In contrast, a germ cell origin is often hard to prove in metastatic GCTs that have developed so‐called somatic malignant transformation. A high percentage, up to 89%, of GCTs are characterised by the appearance of isochromosome 12p [i(12p)]. Fluorescence in‐situ hybridisation has been the most common diagnostic method for the detection of i(12p) so far, but has the disadvantages of being time‐consuming, demanding, and not being a stand‐alone method. The aim of the present study was to establish a quantitative real‐time polymerase chain reaction assay as an independent method for detecting i(12p) and regional amplifications of the short arm of chromosome 12 by using DNA extracted from formalin‐fixed paraffin‐embedded tissue. Methods and results: A cut‐off value to distinguish between the presence and absence of i(12p) was established in a control set consisting of 36 tumour‐free samples. In a training set of 149 GCT samples, i(12p) was detectable in 133 tumours (89%), but not in 16 tumours (11%). In a test set containing 27 primary and metastatic GCTs, all 16 tumours with metastatic spread and/or somatic malignant transformation were successfully identified by the detection of i(12p). Conclusion: In summary, the qPCR assay presented here can help to identify, further characterise and assign a large proportion of histologically inconclusive malignancies to a GCT origin. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
300. What radiologists should know about microRNA (miRNA) serum biomarkers for germ cell tumors.
- Author
-
Morgan, Matthew A., Garratt, Joanie M., and Vaughn, David J.
- Subjects
TERATOCARCINOMA ,ALPHA fetoproteins ,TUMOR markers ,BIOMARKERS ,MICRORNA ,RADIOLOGISTS - Abstract
MicroRNAs expressed by germ cell tumors represent a novel approach to detection of metastatic disease during staging, surveillance, and recurrence post-therapy. It has particular promise in settings of equivocal imaging, such as clinical stage I GCT, tumor marker negative stage IIA, or after chemotherapy. These miRNAs have the potential to change typical serum marker evaluation and imaging surveillance schedules. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.